Sabbath K D, Ball E D, Larcom P, Davis R B, Griffin J D
J Clin Invest. 1985 Feb;75(2):746-53. doi: 10.1172/JCI111756.
The expression of differentiation-associated surface antigens by the clonogenic leukemic cells from 20 patients with acute myeloblastic leukemia (AML) was studied with a panel of seven cytotoxic monoclonal antibodies (anti-Ia, -MY9, -PM-81, -AML-2-23, -Mol, -Mo2, and -MY3). The surface antigen phenotypes of the clonogenic cells were compared with the phenotypes of the whole leukemic cell population, and with the phenotypes of normal hematopoietic progenitor cells. In each case the clonogenic leukemic cells were found within a distinct subpopulation that was less "differentiated" than the total cell population. Clonogenic leukemic cells from different patients could be divided into three phenotype groups. In the first group (7 of 20 cases), the clonogenic cells expressed surface antigens characteristic of the normal multipotent colony-forming cell (Ia, MY9). These cases tended to have "undifferentiated" (FAB M1) morphology, and the total cell population generally lacked expression of "late" monocyte antigens such as MY3 and Mo2. A second group (seven cases) of clonogenic cells expressed surface antigens characteristic of an "early" (day 14) colony-forming unit granulocyte-monocyte (CFU-GM), and a third group (six cases) was characteristic of a "late" (day 7) CFU-GM. The cases in these latter two groups tended to have myelomonocytic (FAB M4) morphology and to express monocyte surface antigens. These results suggest that the clonogenic cells are a distinct subpopulation in all cases of AML, and may be derived from normal hematopoietic progenitor cells at multiple points in the differentiation pathway. The results further support the possibility that selected monoclonal antibodies have the potential to purge leukemic clonogenic cells from bone marrow in some AML patients without eliminating critical normal progenitor cells.
用一组七种细胞毒性单克隆抗体(抗-Ia、-MY9、-PM-81、-AML-2-23、-Mol、-Mo2和-MY3)研究了20例急性髓细胞白血病(AML)患者的克隆性白血病细胞分化相关表面抗原的表达。将克隆性细胞的表面抗原表型与整个白血病细胞群体的表型以及正常造血祖细胞的表型进行了比较。在每种情况下,克隆性白血病细胞都存在于一个与总细胞群体相比“分化程度较低”的独特亚群中。来自不同患者的克隆性白血病细胞可分为三个表型组。在第一组(20例中的7例)中,克隆性细胞表达正常多能集落形成细胞的特征性表面抗原(Ia、MY9)。这些病例往往具有“未分化”(FAB M1)形态,并且总细胞群体通常缺乏“晚期”单核细胞抗原如MY3和Mo2的表达。第二组(7例)克隆性细胞表达“早期”(第14天)粒细胞-单核细胞集落形成单位(CFU-GM)的特征性表面抗原,第三组(6例)具有“晚期”(第7天)CFU-GM的特征。后两组的病例往往具有粒单核细胞(FAB M4)形态并表达单核细胞表面抗原。这些结果表明,克隆性细胞在所有AML病例中都是一个独特的亚群,并且可能在分化途径的多个点上源自正常造血祖细胞。这些结果进一步支持了在某些AML患者中,选择的单克隆抗体有可能在不消除关键正常祖细胞的情况下从骨髓中清除白血病克隆性细胞的可能性。